News
Public · Published
Barclays maintains Axon Enterprise at Overweight, lowers price target to $507 from $688
Barclays kept its Overweight rating on Axon Enterprise but cut its price target to $507 from $688, a 26.3% reduction. The new target implies 62.0% upside from Axon's Nov. 6 closing price of $313.
Published:
Updated:
What happened
Barclays kept its Overweight rating on Axon Enterprise but cut its price target to $507 from $688, a 26.3% reduction. The new target implies 62.0% upside from Axon’s Nov. 6 closing price of $313.
Confirmed
Global impact / market context
The lower target signals that Barclays now sees less value in Axon than before, even while retaining its positive rating. Analyst targets can shape investor expectations, but they do not change Axon’s sales, costs, or cash available unless investors act on them or the company’s results change.
Analyst inference
Recent targets in the article span $500 to $800 across five analyst notes from the past 30 days. Barclays’ $507 target sits near the low end of that range, while the rating remains Overweight, a recommendation to hold more shares than a benchmark allocation.
Confirmed
What to watch
- Compare Axon’s upcoming business results with the assumptions behind Barclays’ lower target; weaker revenue or rising costs could provide a business reason for the cut. Analyst inference
- Watch for further analyst updates: the five recent targets range from $500 to $800, so additional revisions could alter expectations for Axon’s shares. Analyst inference
- Check whether Barclays changes its Overweight rating in a later update; the supplied article says the rating was maintained alongside the lower target. Confirmed
Evidence
- Original source link unavailable